NCT01455142View on ClinicalTrials.gov

A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin degludec/insulin aspart

Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).

Trial Locations (1)

8010

Graz